Printer Friendly

ROBERTS PHARMACEUTICAL CORPORATION APPOINTS VICE PRESIDENT, DEVELOPMENTAL THERAPEUTICS

 EATONTOWN, N.J., June 2 /PRNewswire/ -- Roberts Pharmaceutical Corporation (NASDAQ: RPCX) announced the appointment of Dr. Jerome Wilson as vice president, developmental therapeutics. In his new position Dr. Wilson will assume full responsibility for all activities of what was previously known as the company's research and development department. Inasmuch as Roberts Pharmaceutical does no basic research, the designation of the company's development activities as developmental therapeutics more accurately reflects the department's functions, responsibilities and activities.
 Dr. Wilson has over 15 years of pharmaceutical industry experience. He has held various senior level positions with Warner-Lambert Company including, most recently, director of biostatistics and clinical data management. Throughout his professional career, Dr. Wilson has authored a significant number of scientific publications and has made a variety of professional presentations pertaining to his field of expertise. Dr. Wilson is frequently called upon by the National Cancer Institute to serve on various review committees to assist in the evaluation of investigator initiated research and the awarding of cancer center grants.
 Dr. Wilson received his undergraduate degree in Chemistry from Dillard University, received his masters degree in Immunology from Harvard University School of Medicine and received his Ph.D. in Cancer-Occupational Epidemiology from the University of North Carolina, at Chapel Hill. Dr. Wilson currently resides in the Morristown, N.J. area and is planning to relocate to the Monmouth County area in the near future.
 Roberts Pharmaceutical is an international pharmaceutical company focusing on the acquisition and development of high-potential, undervalued, late-stage development products and the acquisition of currently marketed prescription and nonprescription products. Roberts has seven drugs in late stage clinical development and currently markets over 100 different products for urological therapy, pain management, cough/cold, gastrointestinal disease, endocrine disorders and dermatological conditions.
 -0- 6/2/93
 /CONTACT: Anthony P. Maris of Roberts Pharmaceutical, 908-389-1182/
 (RPCX)


CO: Roberts Pharmaceutical Corporation ST: New Jersey IN: MTC SU: PER

SM -- NY057 -- 4505 06/02/93 13:28 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jun 2, 1993
Words:322
Previous Article:GALVESTON-HOUSTON ACQUIRES ASSETS OF DIVISION OF HYDRIL AND TERMINATION OF NEGOTIATIONS TO ACQUIRE TOTAL ENGINEERING SERVICES TEAM, INC.
Next Article:AMEX BEGINS SEARCH FOR NEW CHAIRMAN TO SUCCEED JONES FOLLOWING CLINTON'S ANNOUNCEMENT HE INTENDS TO NOMINATE HIM AS U.S. AMBASSADOR TO MEXICO
Topics:

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters